# A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

> **NCT00068484** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** topotecan hydrochloride
- **DRUG:** bortezomib
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00068484
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068484, "A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00068484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*